Bharat Biotech Receives DCGI's Approval For Phase 2/3 Clinical Trial Of Covaxin In Children Aged 2 To 18 Yrs

Bharat Biotech Receives DCGI's Approval For Phase 2/3 Clinical Trial Of Covaxin In Children Aged 2 To 18 Yrs

source https://news.abplive.com/health/coronavirus-vaccine-bharat-biotech-receives-dcgi-s-approval-for-phase-2-3-clinical-trial-of-covaxin-in-children-aged-2-to-18-yrs-1458116